drugset / Trial / NCT00648427
Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's paroxetine hydrochloride controlled-release 25 mg tablets to GSK's Paxil CR™ 25 mg tablets following a single, oral 25 mg (1 x 25 mg) dose administered under fasting conditions.
Timeline
- Start
- 2005-04
- Primary completion
- 2005-04
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paroxetine | Small molecule | 25 mg | Oral |
Indications
No indication recorded.